Marquette Asset Management, LLC Tcr2 Therapeutics Inc. Transaction History

Marquette Asset Management, LLC

  • $629 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Jul 15, 2022
BUY
$2.11 - $2.94 $14,561 - $20,288
6,901 Added 20.75%
40,163 $116,000
Q1 2022

Apr 26, 2022
BUY
$2.4 - $4.71 $31,879 - $62,562
13,283 Added 66.48%
33,262 $92,000
Q4 2021

Jan 19, 2022
BUY
$4.58 - $8.34 $91,503 - $166,624
19,979 New
19,979 $93,000

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Marquette Asset Management, LLC Portfolio

Follow Marquette Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marquette Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Marquette Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email